About us Contacts Drug interactions: 390 212
Drug search by name

Afinitor and Fedratinib

Determining the interaction of Afinitor and Fedratinib and the possibility of their joint administration.

Check result:
Afinitor <> Fedratinib
Relevance: 15.10.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent or moderate inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus. The risk of side effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia may be increased. MANAGEMENT: The use of everolimus with potent or moderate inhibitors of CYP450 3A4 and/or P-glycoprotein such as protease inhibitors, macrolide antibiotics, and azole antifungal agents should generally be avoided. References "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.

Professional:

GENERALLY AVOID: Coadministration with potent or moderate inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus. The risk of side effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia may be increased.

MANAGEMENT: The use of everolimus with potent or moderate inhibitors of CYP450 3A4 and/or P-glycoprotein such as protease inhibitors, macrolide antibiotics, and azole antifungal agents should generally be avoided.

References
  • "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.
Afinitor

Generic Name: everolimus

Brand name: Afinitor, Afinitor Disperz, Zortress

Synonyms: n.a.

Fedratinib

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction